MacroGenics, Inc. (MGNX)
4.14
+0.01
(+0.24%)
USD |
NASDAQ |
Sep 18, 16:00
4.14
0.00 (0.00%)
After-Hours: 20:00
MacroGenics Enterprise Value : 288.44M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 288.44M |
| September 17, 2026 | 287.80M |
| September 16, 2026 | 284.62M |
| September 15, 2026 | 282.07M |
| September 14, 2026 | 292.25M |
| September 11, 2026 | 279.52M |
| September 10, 2026 | 277.62M |
| September 09, 2026 | 286.53M |
| September 08, 2026 | 299.89M |
| September 04, 2026 | 304.98M |
| September 03, 2026 | 295.44M |
| September 02, 2026 | 299.89M |
| September 01, 2026 | 282.07M |
| August 31, 2026 | 278.89M |
| August 28, 2026 | 287.80M |
| August 27, 2026 | 284.62M |
| August 26, 2026 | 282.07M |
| August 25, 2026 | 290.34M |
| August 24, 2026 | 280.80M |
| August 21, 2026 | 285.89M |
| August 20, 2026 | 283.98M |
| August 19, 2026 | 290.34M |
| August 18, 2026 | 285.25M |
| August 17, 2026 | 283.34M |
| August 14, 2026 | 293.53M |
| Date | Value |
|---|---|
| August 13, 2026 | 284.62M |
| August 12, 2026 | 280.80M |
| August 11, 2026 | 274.43M |
| August 10, 2026 | 284.62M |
| August 07, 2026 | 282.07M |
| August 06, 2026 | 280.16M |
| August 05, 2026 | 273.16M |
| August 04, 2026 | 273.16M |
| August 03, 2026 | 268.07M |
| July 31, 2026 | 259.79M |
| July 30, 2026 | 265.52M |
| July 29, 2026 | 258.52M |
| July 28, 2026 | 269.98M |
| July 27, 2026 | 279.52M |
| July 24, 2026 | 260.43M |
| July 23, 2026 | 280.16M |
| July 22, 2026 | 298.62M |
| July 21, 2026 | 313.89M |
| July 20, 2026 | 299.89M |
| July 17, 2026 | 310.71M |
| July 16, 2026 | 287.16M |
| July 15, 2026 | 299.89M |
| July 14, 2026 | 297.98M |
| July 13, 2026 | 311.35M |
| July 10, 2026 | 300.53M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 207.57B |
| Xencor, Inc. | 1.551B |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -69.64M |
| Revenue (Quarterly) | 32.83M |
| Total Expenses (Quarterly) | 102.47M |
| EPS Diluted (Quarterly) | 0.3069 |
| Gross Profit Margin (Quarterly) | 97.84% |
| Profit Margin (Quarterly) | -212.1% |
| Earnings Yield | -5.57% |
| Normalized Earnings Yield | -5.565 |